Labcorp launches new test to identify and confirm neurodegenerative disease

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 13, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of the first widely accessible test that provides direct evidence of neurodegeneration and neuronal injury.

Redi.Health collaborates with Labcorp to seamlessly connect patients and providers

COLUMBUS, O.H., July 12, 2022 — Today, Redi.Health, provider of health management technology that improves total patient health, is announcing a collaboration with Labcorp, a leading global life sciences company. Through this combined effort, Labcorp Drug Development’s Patient Access Solutions will integrate Redi.Health’s digital support platform to offer patients and their care providers a variety of digital and traditional communications channels and tools with real-time data synching to help patients better manage their health.

Labcorp forms strategic partnership with MD Anderson Cancer Center Foundation Spain to increase access to early phase oncology clinical trials

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 11, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced it has formed a strategic partnership with MD Anderson Cancer Center Foundation Spain, a non-profit organization whose objectives are to beat cancer and to increase accessibility of early phase oncology clinical trials.

Labcorp first national laboratory to offer monkeypox test

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 6, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s ( CDC ) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox.

Labcorp plans laboratory expansion in Japan through BML collaboration

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 28, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.

Tigerlily Foundation and Labcorp collaborate to increase clinical trial diversity for women of color

BURLINGTON, N.C. & ALDIE, Va. --(BUSINESS WIRE)--Jun. 24, 2022-- Labcorp , a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color

Labcorp enhances clinical trial and drug development capabilities through real-world data collaboration with HealthVerity

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 21, 2022-- Labcorp ® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity , Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs.

Media Statement: Labcorp receives FDA Emergency Use Authorization for first COVID-19 test to identify specific SARS-CoV-2 lineages

BURLINGTON, N.C.,  June 14, 2022 — On Friday, June 10, 2022, Labcorp, a global life sciences company, received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II sequencing system.

Labcorp expands access to comprehensive genomic testing through new lung cancer program

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 2, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, understands the important and growing role of precision medicine and is working to ensure more people have access to targeted and personalized treatments.

Labcorp signs statement of support for guard and reserve members

BURLINGTON, N.C., May 26, 2022 — North Carolina Employer Support of the Guard and Reserve (ESGR), a United States Department of Defense program, announced today that Labcorp, a global life sciences company, signed a Statement of Support for the Guard and Reserve at its corporate headquarters in Burlington, N.C. Representatives of Labcorp’s Veteran Employee Resource Group (VERG) and others attended this event in person and virtually.